Morlay Pharmaceutical Private Limited
About Morlay Pharmaceutical Private Limited
Data last updated:
Morlay Pharmaceutical Private Limited is a private limited company based in Dehradun, Uttarakhand, India. The company is currently under process of striking off by the Registrar of Companies. The removal process has been initiated but is not yet final, and the company may be struck off soon. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 19 November 2018.
The company is registered with the Registrar of Companies (ROC), Uttarakhand, under CIN U74999UR2018PTC009223. Its GSTIN is 05AAMCM2377D2ZH (Uttarakhand). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Raghawendr Maurya Kumar and Ekta Maurya.
Its last annual general meeting (AGM) was held on 29 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Dehradun, Uttarakhand.
As per the financials filed for FY 2025, the company reported a revenue of ₹4.56 Lakh, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹3.1 Lakh (net margin 67.9%) and EBITDA of ₹3.11 Lakh (EBITDA margin 68.2%). Revenue has grown at a compounded annual rate (CAGR) of 141% over three years and 84% over five years.
Company details
Contact details
Morlay Pharmaceutical Private Limited's registered office is in Dehradun, Uttarakhand. Its e-mail address is in the company report.
- Email
- Registered AddressKhasra No. 2067/1 Khata No. 704 Green Avenue Colony Pattionwala Chandr, Abani, Dehradun, Uttarakhand, India – 248002
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Morlay Pharmaceutical Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Morlay Pharmaceutical is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Morlay Pharmaceutical Private Limited, buy the company report.
Financials of Morlay Pharmaceutical Private Limited
FY 2025 filings availableMorlay Pharmaceutical Private Limited reported revenue of ₹4.56 Lakh (up 1466% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 84% over five years. EBITDA rose 418% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.11 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹3.1 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 68.2% | ||||
| Net Profit Margin | 67.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Morlay Pharmaceutical Private Limited, buy the company report.
Board of directors of Morlay Pharmaceutical Private Limited
Morlay Pharmaceutical has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Raghawendr Maurya Kumar Also directs: Morlay India Private Limited | Director | 19 Nov 2018 | 7 Years 11 Months | Current |
| Ekta Maurya Also directs: Morlay India Private Limited | Director | 19 Nov 2018 | 7 Years 11 Months | Current |
Peer comparison
Morlay Pharmaceutical Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Urmila Greens Private Limited | ₹4.57 Lakh (FY 2022) | Tirtol, Odisha, India | ||||
| Kelpways Labs Private Limited | ₹4.56 Lakh (FY 2025) | 22.0% | Lucknow, Uttar Pradesh, India | |||
| Into Dreams Private Limited | ₹4.56 Lakh (FY 2019) | Hyderabad, Telangana, India | ||||
| Virucham Mara Cheku Oil Private Limited | ₹4.56 Lakh (FY 2024) | -21.0% | Chennai, Tamil Nadu, India | |||
| Vasthan Business Solutions Private Limited | ₹4.56 Lakh (FY 2022) | Palanpur, Gujarat, India | ||||
| Morlay Pharmaceutical Private Limitedthis company | ₹4.56 Lakh (FY 2025) | ₹3.1 Lakh | 67.9% | 1466.0% | Dehradun, Uttarakhand, India | |
| Pyd Recyclers Private Limited | ₹4.56 Lakh (FY 2023) | 145.0% | Lucknow, Uttar Pradesh, India | |||
| Dhaksha E-Com Multitrade Private Limited | ₹4.56 Lakh (FY 2021) | Hyderabad, Telangana, India | ||||
| Poshluxe Private Limited | ₹4.56 Lakh (FY 2024) | New Delhi, Delhi, India | ||||
| Canopy Research Laboratories Private Limited | ₹4.56 Lakh (FY 2025) | -86.0% | Kanpur, Uttar Pradesh, India | |||
| Soiedko Ventures Private Limited | ₹4.56 Lakh (FY 2025) | 55.0% | Thiruvananthapuram, Kerala, India |
To see the full peer comparison of Morlay Pharmaceutical Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Morlay Pharmaceutical Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Morlay Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Morlay Pharmaceutical has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AAMCM2377D2ZH | Uttarakhand | Active | 31 Mar 2022 |
To see the full GST registrations and return filing status of Morlay Pharmaceutical Private Limited, buy the company report.
Recent activity
Morlay Pharmaceutical Private Limited has 2 board changes on record since 2018: 2 appointments. The latest: Ekta Maurya was appointed as Director on 19 Nov 2018.
Frequently asked questions
Morlay Pharmaceutical is currently "Under Process of Striking Off" as per MCA records. The Registrar of Companies has initiated the process to remove the company from the register, typically due to non-filing of statutory returns. This process is not yet final, but the company may be struck off soon. Caution is advised before entering into any agreements with this entity.
Morlay Pharmaceutical is a company pending strike off, currently registered as a private limited company based in Dehradun, Uttarakhand, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 19 November 2018 and is registered under CIN U74999UR2018PTC009223. The company may be struck off soon - caution is advised.
Morlay Pharmaceutical has 2 current directors:
- Raghawendr Maurya Kumar - Director
- Ekta Maurya - Director
The CIN (Corporate Identification Number) of Morlay Pharmaceutical is U74999UR2018PTC009223. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Morlay Pharmaceutical was incorporated on 19 November 2018. It is registered with the Registrar of Companies, Uttarakhand.
The registered office of Morlay Pharmaceutical is at Khasra No. 20671 Khata No. 704 Green Avenue Colony Pattionwala Chandr, Abani, Dehradun, Uttarakhand, India – 248002.
The latest financial statements of Morlay Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 July 2025. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Morlay Pharmaceutical is 05AAMCM2377D2ZH, registered in Uttarakhand. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
Morlay Pharmaceutical operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
The peers of Morlay Pharmaceutical by revenue are Urmila Greens Private Limited, Kelpways Labs Private Limited, Into Dreams Private Limited, Virucham Mara Cheku Oil Private Limited, Vasthan Business Solutions Private Limited and 5 more, all in the same principal business activity (wholesale trading).
Ekta Maurya was appointed as Director on 19 Nov 2018. Raghawendr Maurya Kumar was appointed as Director on 19 Nov 2018.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
